Vivos Therapeutics Share Price (NASDAQ: VVOS)

$4.33

▲

-0.31

(-6.68%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Vivos Therapeutics Stock chart to analyse performance

Vivos Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$4.25
Today's High:$4.65
$4.33
1.85%
Downside
Day's Volatility :8.6%
Upside
6.88%
52 Weeks Low:$1.98
52 Weeks High:$7.95
$4.33
54.27%
Downside
52 Weeks Volatility :75.09%
Upside
45.53%

Vivos Therapeutics Stock Returns

Period	Vivos Therapeutics Inc	Index (Russel 2000)
3 Months	80.21%	0.0%
6 Months	31.06%	0.0%
1 Year	66.03%	0.0%
3 Years	-85.34%	-4.7%

Vivos Therapeutics Inc Key Stats

Check Vivos Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$4.64
Open	$4.65
Today's High	$4.65
Today's Low	$4.25
Market Capitalization	$34.8M
Today's Volume	$96.8K
52 Week High	$7.95
52 Week Low	$1.98
Revenue TTM	$14.4M
EBITDA	$-13.5M
Earnings Per Share (EPS)	$-1.16
Profit Margin	-99.5%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-262.05%

Stock Returns calculator for Vivos Therapeutics Stock including INR - Dollar returns

The Vivos Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Vivos Therapeutics investment value today

Current value as on today

₹1,71,185

Returns

₹71,185

(+71.18%)

Returns from Vivos Therapeutics Stock

₹65,900 (+65.9%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Vivos Therapeutics Stock

-65%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Vivos Therapeutics Stock from India on INDmoney has decreased by -65% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Vivos Therapeutics Inc

Name
Holdings %
Name
Holdings %
Geode Capital Management, LLC
0.97%
Cutter & CO Brokerage, Inc.
0.83%
Vanguard Group Inc
0.72%
Commonwealth Equity Services Inc
0.58%
XTX Topco Ltd
0.35%
Royal Bank of Canada
0.31%

Analyst Recommendation on Vivos Therapeutics Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Vivos Therapeutics(by analysts ranked 0 to 5 stars)

Vivos Therapeutics Share Price Target

What analysts predicted

Upside of 17.78%

Target:

$5.10

Current:

$4.33

Vivos Therapeutics share price target is $5.10, a slight Upside of 17.78% compared to current price of $4.33 as per analysts' prediction.

Vivos Therapeutics Stock Insights

Price Movement
In the last 3 months, VVOS stock has moved up by 78.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 3.01M → 3.82M (in $), with an average increase of 21.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 5 quarters, -1.93M → -5.01M (in $), with an average decrease of 27.5% per quarter
VVOS vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 163.5% return, outperforming this stock by 249.7%

Vivos Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$11.4M	↑ 200.43%
Net Income	$-10.8M	↑ 25.9%
Net Profit Margin	-94.39%	↑ 130.86%

	FY20	Y/Y Change
Revenue	$13.1M	↑ 14.68%
Net Income	$-12.1M	↑ 12.11%
Net Profit Margin	-92.28%	↑ 2.11%

	FY21	Y/Y Change
Revenue	$16.9M	↑ 29.23%
Net Income	$-20.3M	↑ 68.31%
Net Profit Margin	-120.18%	↓ 27.9%

	FY22	Y/Y Change
Revenue	$16.0M	↓ 5.1%
Net Income	$-23.8M	↑ 17.5%
Net Profit Margin	-148.81%	↓ 28.63%

	FY23	Y/Y Change
Revenue	$13.8M	↓ 13.87%
Net Income	$-13.6M	↓ 43.04%
Net Profit Margin	-98.42%	↑ 50.39%

	FY24	Y/Y Change
Revenue	$15.0M	↑ 8.91%
Net Income	$-11.1M	↓ 18.02%
Net Profit Margin	-74.09%	↑ 24.33%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$3.4M	↑ 5.26%
Net Income	$-3.8M	↓ 11.65%
Net Profit Margin	-110.06%	↑ 21.07%

	Q2 FY24	Q/Q Change
Revenue	$4.1M	↑ 18.57%
Net Income	$-1.9M	↓ 48.71%
Net Profit Margin	-47.61%	↑ 62.45%

	Q3 FY24	Q/Q Change
Revenue	$3.9M	↓ 4.79%
Net Income	$-2.6M	↑ 35.54%
Net Profit Margin	-67.77%	↓ 20.16%

	Q4 FY24	Q/Q Change
Revenue	$3.7M	↓ 4.2%
Net Income	$-2.8M	↑ 8.07%
Net Profit Margin	-76.45%	↓ 8.68%

	Q1 FY25	Q/Q Change
Revenue	$3.0M	↓ 18.44%
Net Income	$-3.9M	↑ 36.68%
Net Profit Margin	-128.12%	↓ 51.67%

	Q2 FY25	Q/Q Change
Revenue	$3.8M	↑ 26.66%
Net Income	$-5.0M	↑ 29.74%
Net Profit Margin	-131.23%	↓ 3.11%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$8.7M	↑ 219.38%

	FY20	Y/Y Change
Profit	$10.4M	↑ 20.28%

	FY21	Y/Y Change
Profit	$12.6M	↑ 21.04%

	FY22	Y/Y Change
Profit	$10.0M	↓ 20.51%

	FY23	Y/Y Change
Profit	$8.3M	↓ 17.45%

	FY24	Y/Y Change
Profit	$9.0M	↑ 9.04%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.9M	↑ 8.27%

	Q2 FY24	Q/Q Change
Profit	$2.7M	↑ 36.86%

	Q3 FY24	Q/Q Change
Profit	$2.3M	↓ 11.96%

	Q4 FY24	Q/Q Change
Profit	$2.1M	↓ 10.15%

	Q1 FY25	Q/Q Change
Profit	$1.5M	↓ 28.04%

	Q2 FY25	Q/Q Change
Profit	$2.1M	↑ 39.83%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-5.3M	↑ 0.5%
Investing Cash Flow	$86.2K	↓ 107.72%
Financing Cash Flow	$4.5M	↓ 14.93%

	FY20	Y/Y Change
Operating Cash Flow	$-5.7M	↑ 6.36%
Investing Cash Flow	$-120.3K	↓ 239.47%
Financing Cash Flow	$23.5M	↑ 426.68%

	FY21	Y/Y Change
Operating Cash Flow	$-15.7M	↑ 177.01%
Investing Cash Flow	$-2.6M	↑ 2068.78%
Financing Cash Flow	$24.2M	↑ 2.68%

	FY22	Y/Y Change
Operating Cash Flow	$-19.6M	↑ 24.48%
Investing Cash Flow	$-924.0K	↓ 64.57%
Financing Cash Flow	$7.4M	↓ 69.57%

	FY23	Y/Y Change
Operating Cash Flow	$-11.9M	↓ 39.01%
Investing Cash Flow	$-853.0K	↓ 7.68%
Financing Cash Flow	$10.9M	↑ 48.51%

	FY24	Y/Y Change
Operating Cash Flow	$-12.7M	↑ 6.24%
Investing Cash Flow	$-568.0K	↓ 33.41%
Financing Cash Flow	$17.9M	↑ 63.65%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-2.5M	↓ 8.44%
Investing Cash Flow	$-151.0K	↓ 8.48%
Financing Cash Flow	$3.6M	↑ 1.88%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-3.0M	↑ 21.14%
Investing Cash Flow	$-60.0K	↓ 60.26%
Financing Cash Flow	$7.4M	↑ 103.58%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-4.2M	↑ 37.37%
Investing Cash Flow	$-192.0K	↑ 220.0%
Financing Cash Flow	$3.8M	↓ 48.82%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-2.9M	↓ 29.78%
Investing Cash Flow	$-165.0K	↓ 14.06%
Financing Cash Flow	$3.1M	↓ 19.36%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-3.8M	↑ 29.12%
Investing Cash Flow	$-122.0K	↓ 26.06%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-3.5M	↓ 7.96%
Investing Cash Flow	$-5.9M	↑ 4740.98%
Financing Cash Flow	$11.5M	-

Vivos Therapeutics Technicals Summary

Sell

Neutral

Buy

Vivos Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Vivos Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vivos Therapeutics Inc	-0.12%	31.06%	66.03%	-85.34%	-98.08%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	5.15%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vivos Therapeutics Inc	NA	NA	NA	-1.8	-2.62	-0.42	NA	0.63
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vivos Therapeutics Inc	Buy	$34.8M	-98.08%	NA	-99.5%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Vivos Therapeutics Inc

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Organization	Vivos Therapeutics
Employees	113
CEO	Mr. R. Kirk Huntsman
Industry	Miscellaneous

Key Management of Vivos Therapeutics Inc

Name	Title
Mr. R. Kirk Huntsman	Co-Founder, Chairman of the Board & CEO
Mr. Bradford K. Amman	CFO, Treasurer & Secretary
Mr. Todd Huntsman	Co-Founder & Senior VP of Product and Technology
Ms. RaeAnn Byrnes	Co-Founder and Senior VP of Events & Clinical Advisory Services
Ms. Susan McCullough	Co-Founder & Executive VP of Operations
Dr. Terry Jones	Senior VP of Human Resources
Mr. Nicholas M. DeGennaro	Senior Vice President of Mergers and Acquisition Group
Ms. Ruth Hembree	Senior Vice President of Practice Services
Mr. John Ballard	Senior Vice President of Technology
Mr. Michael E. Bruhn	Executive VP of Business Operations Integration

Important FAQs about investing in VVOS Stock from India :

What is Vivos Therapeutics share price today?

Vivos Therapeutics share price today is $4.33 as on August 30, 2025 at 1:29 am IST at the close of the market. Vivos Therapeutics share today touched a day high of $4.65 and a low of $4.25.

What is the 52 week high and 52 week low for Vivos Therapeutics share?

Vivos Therapeutics share touched a 52 week high of $7.95 and a 52 week low of $1.98. Vivos Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $4.33, lower by 45.53% versus the 52 week high.

How to invest in Vivos Therapeutics Stock (VVOS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Vivos Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vivos Therapeutics Shares that will get you 0.3464 shares as per Vivos Therapeutics share price of $4.33 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Vivos Therapeutics Stock (VVOS) from India?

Indian investors can start investing in Vivos Therapeutics (VVOS) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Vivos Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Vivos Therapeutics share’s latest price of $4.33 as on August 30, 2025 at 1:29 am IST, you will get 2.3095 shares of Vivos Therapeutics. Learn more about fractional shares .

What are the returns that Vivos Therapeutics has given to Indian investors in the last 5 years?

Vivos Therapeutics stock has given -98.08% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?